NCT05217628 is a Phase 2, PHASE3 clinical trial of Basimglurant in Trigeminal Neuralgia, sponsored by Noema Pharma AG.

Who is sponsoring NCT05217628?

NCT05217628 is sponsored by Noema Pharma AG.

What drugs are being tested in NCT05217628?

Interventions in NCT05217628: Basimglurant, Placebo.

What condition does NCT05217628 study?

NCT05217628 studies Trigeminal Neuralgia.

Is NCT05217628 still recruiting?

NCT05217628 is currently active, enrolled. Last updated 23 January 2026.

Last reviewed 2026-01-23 · How we verify

NCT05217628

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

Active, enrolled Phase 2, PHASE3 Last updated 23 January 2026

What this trial tests

Phase 2, PHASE3 trial testing Basimglurant in Trigeminal Neuralgia in 166 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

11 January 2022

Primary endpoint
2 February 2027

24 April 2027

Quick facts

Lead sponsor	Noema Pharma AG
Phase	Phase 2, PHASE3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	166
Start date	11 January 2022
Primary completion	2 February 2027
Estimated completion	24 April 2027
Sites	34 locations across Denmark, Italy, United Kingdom, Germany, Poland, United States, Turkey (Türkiye), Spain

Drugs / interventions tested

Basimglurant — full drug profile →
Placebo

Conditions studied

Trigeminal Neuralgia — all drugs for Trigeminal Neuralgia →

Sponsor

Noema Pharma AG — full company profile →

Who can join

Adults 18 to 75, any sex, with Trigeminal Neuralgia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Trigeminal neuralgia (TN), also called "tic douloureux", is the most common form of craniofacial neuropathic pain and is considered the cause of one of the most painful afflictions known in medical practice. This study is designed to evaluate the efficacy and safety of 1.5mg - 3.5mg basimglurant in adults with TN.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.
Xie X, Yu T, Li X, Zhang N, et al · · 2023 · cited 246× · PMID 37669923 · DOI 10.1038/s41392-023-01589-z
Potential novel therapeutic strategies for neuropathic pain.
Du Z, Zhang J, Han X, Yu W, et al · · 2023 · cited 15× · PMID 37152429 · DOI 10.3389/fnmol.2023.1138798
Pharmacology, Signaling and Therapeutic Potential of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators.
Kos JA, Langiu M, Hellyer SD, Gregory KJ. · · 2024 · cited 3× · PMID 39698283 · DOI 10.1021/acsptsci.4c00213
Abstracts from the 18 th European Headache Congress (EHC) : Rotterdam, The Netherlands. 4-7 December 2024.
· 2025 · cited 1× · PMID 40545525 · DOI 10.1186/s10194-025-02062-8
Qualitative validation of TnED©, an electronic instrument capturing pain dimensions in patients with trigeminal neuralgia.
Tahiri AS, Dodhia SA, Chotaliya S, Ansari H, et al · · 2026 · PMID 42220290 · DOI 10.22514/jofph.2026.038

Verify or expand the search:

Other recruiting trials for Trigeminal Neuralgia

Currently open trials in the same condition.

NCT07252453 — Comparison b/w Carbamazepine vs Oxcarbazepine in Treatment of Trigeminal Neuralgia · NA · active not recruiting
NCT06684275 — Comparison of Pulsed and Thermal Radiofrequency for Trigeminal Neuralgia · NA · recruiting
NCT06620172 — CT-guided vs Fluoroscopy-guided Trigeminal Ganglion Radiofrequency Thermocoagulation for Idiopathic Trigeminal Neuralgia · NA · recruiting
NCT06849219 — Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia · Phase 4 · active not recruiting
NCT06216886 — OnabotulinumtoxinA for Trigeminal Neuralgia · Phase 4 · recruiting

Other Noema Pharma AG trials

Trials by the same sponsor.

NCT06385795 — A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause · Phase 2 · completed
NCT05583955 — A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus) · Phase 2 · completed
NCT05059327 — Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC · Phase 2 · completed
NCT06019338 — A Study to Validate a Pain Diary for Patient With Trigeminal Neuralgia · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05217628 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Noema Pharma AG
Last refreshed: 23 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05217628.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing